News

How policy, philanthropy, and scientific collaboration are reshaping the cancer research landscape and why early detection can be the difference between life and death. Twenty years ago, I received a diagnosis that changed everything and led me to dedicate the…

Timing of radiotherapy administration may significantly influence treatment efficacy in breast and prostate cancer. A Spanish study, published in Nature Communications, demonstrates that circadian oscillation of Cryptochrome 1 (CRY1) modulates DNA double-strand break (DSB) repair, making radiotherapy more effective in…

In oncology, progress is measured in survival rates, response curves, and treatment gains. But those numbers rest on a quieter assumption: that health systems can deliver what science makes possible. When they cannot, progress becomes uneven—not in discovery, but in…

In oncology, some ideas arrive too early. For decades, cancer vaccines were one of them. The concept was elegant: train the immune system to recognise tumour cells, much like it recognises viruses, and allow it to eliminate disease with precision…

25 Years of TKIs in CML: A Revolution and a Responsibility Twenty-five years ago, the arrival of imatinib changed the course of a disease and the lives of countless people diagnosed with it. Chronic myeloid leukemia (CML), once defined by…

In oncology, we are trained to deliver hope alongside difficult truths. We speak about survival rates, probabilities, and outcomes. In conflict settings, those terms lose stability. What does survival mean when hospitals are destroyed, treatments cannot reach patients, and people…

In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…

Scientific discovery drives oncology forward, but progress only truly begins when knowledge is turned into action. Every issue of CancerWorld explores the people, ideas, and systems shaping the future of oncology. Scientific breakthroughs remain essential, but their true value emerges…

Chimeric antigen receptor natural killer T (CAR-NKT) cell therapy, a novel form of immunotherapy, is emerging as a promising ‘off-the-shelf’ treatment for patients with pancreatic cancer. In a study published in PNAS, November 21, 2025, U.S. investigators report that CAR-NKT cells…

Where progress is measured not just in science, but in vision, leadership, and care. Every issue of CancerWorld explores people, policies, and practices shaping the future of oncology. In our February issue of CancerWorld, we turn our attention to leadership,…